CRDF Earnings & Financial Statements
Cardiff Oncology, Inc.
$0.97
-$0.04(-3.62%)
35
Overall
60
Value
10
Tech
36
Quality
Market Cap
$75.73M
Volume
412.91K
52W Range
$0.76 - $3.31
Target Price
$6.28
CRDF earnings and financial statements: Cardiff Oncology, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
CRDF Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $593.0K | $683.0K | $488.0K | $386.0K | $359.0K |
| Operating income | -$48.96M | -$48.65M | -$45.41M | -$39.90M | -$28.86M |
| EBITDA | -$44.95M | -$44.49M | -$50.13M | -$39.67M | -$28.40M |
| Net income | -$45.85M | -$45.43M | -$41.44M | -$38.70M | -$28.29M |
| EPS (diluted) | $-0.69 | $-0.95 | $-0.93 | $-0.89 | $-0.73 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $61.88M | $97.19M | $81.64M | $116.19M | $149.54M |
| Total liabilities | $16.50M | $14.24M | $11.90M | $9.85M | $9.13M |
| Shareholders’ equity | $45.39M | $82.95M | $69.74M | $106.34M | $140.42M |
| Cash and equivalents | $17.47M | $51.47M | $21.66M | $16.35M | $11.94M |
| Long-term debt | $102.0K | $813.0K | $1.46M | $2.04M | $2.57M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$37.92M | -$37.69M | -$30.89M | -$33.82M | -$23.04M |
| Capital expenditure | -$44.0K | -$80.0K | -$582.0K | -$1.01M | -$205.0K |
| Free cash flow | -$37.97M | -$37.77M | -$31.47M | -$34.83M | -$23.25M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CRDF | $0.97 | -3.6% | 412.91K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |